Email

With These Three Tech Plays, We’re Keeping Our Promise

13 | By Michael A. Robinson

When we began this journey together a few months ago we started with a -single powerful concept.

Fifty-seven percent of U.S. workers have less than $25,000 in saving – a reality that sentences those folks to a lifetime of vulnerability and fear.

After reading that, we vowed to help you dodge that bleak fate.

The key, we knew, was the U.S. tech sector.

From the light bulb to the semiconductor to advanced sensors, America’s Silicon Valley has churned out a steady stream of innovations that turned ordinary people into millionaires – sometimes virtually overnight.

So we identified seven powerful high-tech trends. And then we used my years of experience as a Silicon Valley insider to create five immutable rules we could use to identify double-your-money profit opportunities.

As we’ll show you in an upcoming report, our strategy has already generated some impressive gains. And there’s more to come.

The road to wealth, as we like to say, is paved by tech.

And today is the next phase of this journey.

I see still more growth in the New Year, particularly in the global tech sector.

With that in mind, I wanted to talk with you today about my three favorite profit plays for 2014 – recommendations that I believe will pack a punch for your portfolio.

So without additional introduction, let’s get down to business – because we don’t want you to be part of the ill-fated 57%.

And with the Strategic Tech Investor working on your behalf, there’s no need to be …

A Heck of a Year

When we unveiled our strategy back in the spring, I said you could get started immediately. The reason: I was predicting that 2013 would be a strong year for tech stocks.

I was right.

The tech-focused Nasdaq Composite Index has gained nearly 33.5% this year – in spite of such challenges as the U.S. “Fiscal Cliff,” the scandalously flawed rollout of Obamacare, and the longstanding worries about a U.S. central bank tapering, to name just a few.

When you compare that with the challenges we faced along the way — the Fiscal Cliff in Washington and fears of Fed tapering just to name a couple — that was a truly great performance.

And the gains aren’t going to end there.

Tech investors stand to make a lot of money in the New Year as Silicon Valley innovators continue to create all sorts of new tech-based products and services.

Not surprisingly, the seven high-tech trends we identified earlier this year helped us define these newest picks.

And we’ll start with “The Cloud.”

Out in Space – Cyberspace, That Is…

One of the “quiet revolutions” taking place in tech has to do with how all the “stuff” that we use online is accessed and stored. And it’s a big deal.

Businesses no longer have to buy, set up and run their own computer networks. Instead, they’re tapping the power of the Cloud.

Cloud computing refers to an innovation that allows third-party vendors to host applications for clients who can then access them from any place at any time – needing only the usual Internet connection.

It sounds simple. But make no mistake – it’s huge.

The respected research firm Forrester predicts cloud computing will increase from a $41 billion base in 2011 to $241 billion in 2020. We’re talking growth of roughly 487% by the end of this decade

That’s why I think most investors would do well to take a serious look at First Trust ISE Cloud Computing Index Fund (NYSE: SKYY). Trading at $25, this exchange-traded fund (ETF) holds about 40 stocks and serves as a “Who’s Who” of cloud-based firms.

Though it holds some fast-moving smaller caps, the ETF is focused on such major players as Amazon.com Inc. (NasdaqGS: AMZN), which became a Cloud leader by simply renting out the surplus capacity in its massive data centers.

Some other holdings include:

  • Google Inc. (NasdaqGS: GOOG), which also has built a cloud business by turning its huge computer network into an additional revenue stream. With a $360 billion market cap, Google increased its earnings 36% last quarter, in part because of a 24% operating margins.
  • Red Hat Inc. (NasdaqGS: RHT), a leader in providing open-source software that can be accessed and managed via the Cloud. With a $9 billion market cap, Red Hat has a 15% operating margin and $843 million in cash with no debt.
  • Brightcove Inc. (NasdaqGS: BCOV), a specialist in using the Cloud to help firms publish, manage and distribute video. With a market cap of $381 million, the company has negative margins but is growing at nearly 40% a year.

A Bio Blast

The biotech sector was a hot performer in 2013, and you can expect that to carry over into the New Year.

In fact, the cash-rich and cash-needy marketplace will continue to see hefty growth for decades to come.

Mature economies like those of the United States, Japan and Europe offer the industry incredible long-term opportunities through a combination of aging populations, longer lifespans and a deep pipeline of new drugs in development.

And such emerging economies as China offer growth as rising incomes allow consumers to seek better healthcare.

Biotech already plays a huge role in the global economy. Market researcher IBISWorld estimates the industry’s annual world sales at $93 billion. Since 2008, the industry has averaged an annual compound growth rate of 11%.

That’s why I believe First Trust NYSEArca Biotechnology Index (NYSE: FBT) should be in every tech investor’s portfolio.

Priced at about $66, this ETF represents a unique play because it gives us broad biotech exposure with a fund that also takes a very focused approach: It holds just 20 stocks in its portfolio – each accounting for about 5% of the portfolio.

The stocks in FBT have a median market cap of about $6.3 billion. That’s large enough to offer stability but still small enough to deliver plenty of upside. Some key holdings include:

  • Alexion Pharmaceuticals Inc. (NasdaqGS: ALXN), a company focused on ultra-rare diseases. With a market cap of $24 billion, Alexion has a 24% profit margin and return on equity 16%.
  • Gilead Sciences Inc. (NasdaqGS: GILD), which has products that fight HIV/AIDS – as well as liver, heart and respiratory-based diseases. With a market cap of $109 billion, it has a 29% profit margin and last year had free cash flow of about $2.6 billion.
  • Regeneron Pharmaceuticals Inc. (NasdaqGS: REGN), a firm whose main product combats blindness in older people. With a $26 billion market cap of, the firm has a 42% profit margin a return on equity (ROE) of 87%.

The Art of the Deal

As for the third area where investors should do well next year, I recommend you follow the market for high-tech initial-public stock offerings (IPOs). These stock-offering deals did great this year – and I expect them to do just as well in 2014.

In the first nine months of the year, market forecaster PwC said there were 160 IPOs, up 48% from the 108 new stock offerings that took place in the same period last year.

And Dealogic says tech debuts gained an average of 60% this year, compared with the IPO average of 33%. High-tech and bioscience stocks made up about a third of the new stock offerings.

The First Trust IPOX-100 Index Fund (NYSE: FPX) is a great way to play this field. The exchange-traded fund takes advantage of IPOs. Trading at about $44, the ETF has about one third of its cash invested in new tech and health-care issues.

One of the great things about this ETF is that its managers created a disciplined set of rules that sidestep the volatility inherent in newly minted stocks. For instance, the fund only invests in stocks after doing a thorough review of the company’s financials and never buys on opening day.

By definition, the fund does not heavily invest in the sexiest small and micro-cap firms. Instead, the ETF is weighted toward mid-caps with an average market valuation of roughly $3.3 billion. The fund’s top holdings have generated excellent gains, including:

  • Facebook Inc. (NasdaqGS: FB), the social-networking firm whose shares are up about 40% since going public in May 2012. But it’s gained 98% in the past year.
  • AbbVie Inc. (NYSE: ABBV), the biotech spin-off from drug giant Abbot Laboratories Inc. (NYSE: ABT). AbbVie shares have rallied about 49% since it debuted in January.
  • Tesla Motors Inc. (NasdaqGS: TSLA), the maker of electric cars whose shares are up nearly 670% since going public in July 2010 – even after a recent correction.

Each of these ETFs represents a true investing double play.

On one hand, the access they provide to the hottest tech stocks means you’ll have a chance to earn returns that are far above the market averages. At the same time, however, the diversification they offer means the also represent great foundational plays.

And that’s a great way to start a New Year.

By the way, I’m about to release my tech investing newsletter. It’s called the Nova-X Report. You should definitely check it out here. As you’ll see, we’re all over Bitcoin. But that’s just one of the truly paradigm-changing technologies you’re going to learn about each month.

There’s plenty more coming – lot’s more. And I’ve mapped them all here for you.

See you next week.

[Editor’s Note: The inaugural issue of Michael Robinson’s Nova-X Report tech-investing newsletter will debut in just a few days. In it, Michael will tell his subscribers about a tiny biotech with the most amazing technology. This isn’t one of those “maybe it will hit” biotechs – it already has products on the market and is already making money. But it’s a company you’ll never find on your own. Check it out here.]

13 Responses to With These Three Tech Plays, We’re Keeping Our Promise

  1. Ivan T. Green says:

    I have to really dig into these recommendations. This is a lot to digest. That’s the problem most of us seniors face. So I will keep reading.
    Thanks.

  2. Hla Tin says:

    Have you read about the Low-cost hearing aid that runs on Bluetooth and an app Pg. 35, recent Bloomberg BusinessWeek? Rodney Perkins of Cal. Ear Institute at Stanford Univ. started a few Companies in Silcon Valley with the giants of Science and Technology , with the likes of H-P founders, Intel co-founders, Gordon Moore and CEO Grove; Edward Teller and S. Jobs, etc., is now starting a company in Sound Technology, called Sound ID.
    Since I started losing my hearing in 1993, I looked into this area and even file a device claim for helping the hearing impaired people then, with a device similar to an iPhone,iPad where a caption can be read while listening on the phone for the impaired person.
    I did not follow up on the claims as I was drawn into a different field (Pharmaceutical)where I filed a patent and a generic patent was issued on it.

    I am working in the area of Sound Technology applications (in another field) for chemical separation now.

    I am sure Perkins will be successful in this area to help the hearing impaired, since he is an Otologist. He is 77 years old now. Hla N. Tin,, Ph.D.

  3. Nicholas Moran says:

    I love getting this kind of information and being able to make decisions on how to invest in these companies and E T F’s which is such a help in making money on companies that are the up coming and die hard million dollar companies that few people are talking about in news and on cnbc. thanks for the help and your desire to show people like me how to get ahead.

  4. Tim Hughes says:

    Question: Michael Robinson’s Nova X is part of strategic tech investor?
    Is Oil & Energy Investor, Wall St. Insights & Indictments part of Money Morning or Michael Robinsons.

  5. jeanne says:

    love your info and your ideas.

    I have been looking for some things in Europe especialy England. Let me koww if you have any ideas jcv

  6. ANI says:

    Hi Michael! I really get a kick out of reading all the great info that you and your colleagues provide via the various newsletters and articles you disseminate an almost daily basis and am very glad that I signed up at the Silver membership level to join the “Bitcoin Revolution” and the “Nova-X” family. However, here’s my “dilemma” if you will…as an extremely novice investor with $1,000-$2,000 to start off with, I get everything you’re saying and how it makes sense to take advantage of certain opportunities, etc., but I have absolutely NO CLUE as to how to get started. Meaning, okay, I have this pot of money to get my investing life underway, but where do I physically go to invest it? Am I supposed to just go set up an online trading account (ex. Etrade, Scott Trade, etc.) and then look for the ticker symbols of companies you guys’ recommend? Am I supposed to call somebody at a brokerage house to set up my account and let them know what I’m interested in doing?

    Don’t get me wrong, I’m not some “unknowledgeable” schlub who’s looking to blow his pot of investing money in week one. Far from it in fact…I have multiple graduate degrees and am well-versed in a lot of different areas in life, just not this one. And I do firmly believe that, like other areas I’ve accrued knowledge in over the years, if I can get a real understanding of how to invest my money, trends/signs of what to look for, etc., that I can become really, really proficient at it. I can tell you that my short-term goal (Summer 2014) is to have enough money to begin trading options by next fall. I read the e-book put out by your colleague, Michael Thomsett, and got really excited by the prospects, but just don’t have the minimum $5,000 required to set up the account.

    So, in closing, if you or someone else from the MMP team could get back to me with a timely response, it would be most appreciated. Thanks in advance for your reply and “Happy Holidays!”

    Sincerely,
    ANI
    (Anxious Novice Investor)

  7. Francis Borcalli says:

    I just joined but I appreciate the clarity in the discussion provided with respect to prospective stocks to consider.

  8. Dr Thomas koch says:

    Hi Michael,

    as I am impresswed with your input so far,
    I just have one more question concerning bitcoin.,-being a subscriber of Nova X.
    I am living in Germany / Bonn and just do not know where to buy bitcoin in Germany so far! And I still haven`t got the books of my subscription ?!?

    awaiting your reply
    regards

Leave a Reply

Your email address will not be published. Required fields are marked *